Provided by Tiger Trade Technology Pte. Ltd.

SPYRE THERAPEUTICS INC

45.46
-1.8500-3.91%
Volume:495.49K
Turnover:22.71M
Market Cap:3.57B
PE:-22.96
High:48.47
Open:47.75
Low:44.80
Close:47.31
52wk High:49.31
52wk Low:10.91
Shares:78.54M
Float Shares:72.55M
Volume Ratio:0.57
T/O Rate:0.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9800
EPS(LYR):-1.9755
ROE:-25.17%
ROA:-19.80%
PB:6.38
PE(LYR):-23.01

Loading ...

Spyre Therapeutics to Participate in Upcoming November Investor Conferences

GlobeNewswire
·
Oct 30, 2025

Spyre Therapeutics (SYRE): Valuation Spotlight After New Clinical Data for Lead Anti-TL1A Therapy SPY072

Simply Wall St.
·
Oct 26, 2025

Spyre Therapeutics Reports Positive Six-Month Phase 1 Data for Anti-TL1A Antibody SPY072 in Rheumatic Diseases

Reuters
·
Oct 24, 2025

Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025

GlobeNewswire
·
Oct 24, 2025

Why Spyre Therapeutics (SYRE) Is Up 25.5% After $275 Million Equity Raise to Fund Pipeline Progress

Simply Wall St.
·
Oct 17, 2025

Spyre Therapeutics Closes $316.2 Million Public Offering

MT Newswires Live
·
Oct 16, 2025

Press Release: Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million

Dow Jones
·
Oct 16, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Spyre Therapeutics, Astria, Walmart

Reuters
·
Oct 15, 2025

Spyre Therapeutics Inc - Expects $486.2 Mln in Cash and Equivalents as of Sept 30, 2025 - SEC Filing

THOMSON REUTERS
·
Oct 14, 2025

Spyre Therapeutics Reports Preliminary $486.2 Million in Cash and Securities as of September 30, 2025

Reuters
·
Oct 14, 2025

Spyre Therapeutics Prices $275 Million Share Offering

MT Newswires Live
·
Oct 14, 2025

BRIEF-Spyre Therapeutics Announces Pricing Of $275 Million Public Offering Of Common Stock

Reuters
·
Oct 14, 2025

Spyre Therapeutics Inc - Pricing of 14.9 Mln Shares at $18.50 per Share

THOMSON REUTERS
·
Oct 14, 2025

Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock

THOMSON REUTERS
·
Oct 14, 2025

Spyre Therapeutics Launches Public Offering

MT Newswires Live
·
Oct 14, 2025

BUZZ-Spyre Therapeutics falls after stock offering launch

Reuters
·
Oct 14, 2025

Spyre Therapeutics announces common stock offering, no amount given

TIPRANKS
·
Oct 14, 2025

Spyre Therapeutics Up Over 19%, on Pace for Largest Percent Increase Since November 2023 -- Data Talk

Dow Jones
·
Oct 10, 2025

Halozyme Therapeutics Appoints Cortney Caudill as Chief Operating Officer

Reuters
·
Oct 07, 2025

Spyre Therapeutics announces poster presentations at UEGW 2025

TIPRANKS
·
Oct 06, 2025